Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors
Autore:
Remberger, M; Ringden, O; Blau, IW; Ottinger, H; Kremens, B; Kiehl, MG; Aschan, J; Beelen, DW; Basara, N; Kumlien, G; Fauser, AA; Runde, V;
Indirizzi:
Huddinge Univ Hosp, Dept Clin Immunol, SE-14186 Huddinge, Sweden Huddinge Univ Hosp Huddinge Sweden SE-14186 l, SE-14186 Huddinge, Sweden Huddinge Univ Hosp, Ctr Allogene Stem Cell Transplantat, SE-14186 Huddinge, Sweden Huddinge Univ Hosp Huddinge Sweden SE-14186 t, SE-14186 Huddinge, Sweden Univ Hosp, Dept Bone Marrow Transplantat, Essen, Germany Univ Hosp EssenGermany , Dept Bone Marrow Transplantat, Essen, Germany Univ Hosp, Dept Paediat Haematol & Oncol, Essen, Germany Univ Hosp EssenGermany , Dept Paediat Haematol & Oncol, Essen, Germany Clin Bone Marrow Transplantat Haematol & Oncol, Idar Oberstein, Germany Clin Bone Marrow Transplantat Haematol & Oncol Idar Oberstein Germany y
Titolo Testata:
BLOOD
fascicolo: 6, volume: 98, anno: 2001,
pagine: 1739 - 1745
SICI:
0006-4971(20010915)98:6<1739:NDIGDR>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; BLOOD PROGENITOR CELLS; ALLOGENEIC TRANSPLANTATION; HEMATOLOGIC MALIGNANCIES; RANDOMIZED TRIAL; SINGLE-CENTER; DOUBLE-BLIND; HLA-A; LEUKEMIA; ENGRAFTMENT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
47
Recensione:
Indirizzi per estratti:
Indirizzo: Remberger, M Huddinge Univ Hosp, Dept Clin Immunol, F79, SE-14186 Huddinge, Sweden Huddinge Univ Hosp F79 Huddinge Sweden SE-14186 inge, Sweden
Citazione:
M. Remberger et al., "No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors", BLOOD, 98(6), 2001, pp. 1739-1745

Abstract

The clinical results in 107 patients receiving a peripheral blood stem cell (PBSC) graft mobilized by granulocyte colony-stimulating factor (G-CSF) from HLA-A, -B, and -DR-compatible unrelated donors were compared to 107 matched controls receiving unrelated bone marrow (BMI) transplants. Engraftment was achieved in 94% of the patients in both groups. The PBSC graft contained significantly more nucleated cells, CD34(+), CD3(+), and CD56(+) cells (P < .001), and resulted in a significantly shorter time-to-neutrophil (15 versus 19 days) and platelet engraftment (20 versus 27 days), compared to the BM control group (P < .001). Probabilities of acute graft-versus-host disease (GVHD) grades II to IV were 35% and 32% (not significant [NS]) and ofchronic GVHD 61% and 76% (NS) in the PBSC and BM groups, respectively. There was no difference between the 2 groups in bacteremia, cytomegalovirus reactivation or disease, and fungal infection. The 3-year transplant-related mortality (TRM) rates were 42% in the PBSC group and 31% in the BM controls(P = .7) and the survival rates were 46% and 51%, respectively, The probability of relapse was 25% and 31% in both groups (NS), resulting in disease-free survival rates of 43% in the PBSC group and 46% in the BM controls (NS). In the multivariate analysis, early disease, acute GVHD grade 0 to 1, and presence of chronic GVHD were independent factors associated with a better disease-free survival in this study. PBSC from HLA-compatible unrelated donors can be used safely as an alternative to BM for stem cell transplantation. (C) 2001 by The American Society of Hematology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 10:19:26